Australia's Role in Pneumococcal and Human Papillomavirus Vaccine Evaluation in Asia-Pacific

Overview

Journal Vaccines (Basel)

Date 2021 Aug 28

PMID 34452046

Authors

Zheng Quan Toh

Chau Quang

Joseph A Tooma

Suzanne M Garland

Kim Mulholland

Paul V Licciardi

Affiliations

Soon will be listed here.

Abstract

Australian researchers have made substantial contributions to the field of vaccinology over many decades. Two examples of this contribution relate to pneumococcal vaccines and the human papillomavirus (HPV) vaccine, with a focus on improving access to these vaccines in low- and lower-middle-income countries (LLMICs). Many LLMICs considering introducing one or both of these vaccines into their National Immunisation Programs face significant barriers such as cost, logistics associated with vaccine delivery. These countries also often lack the resources and expertise to undertake the necessary studies to evaluate vaccine performance. This review summarizes the role of Australia in the development and/or evaluation of pneumococcal vaccines and the HPV vaccine, including the use of alternative vaccine strategies among countries situated in the Asia-Pacific region. The outcomes of these research programs have had significant global health impacts, highlighting the importance of these vaccines in preventing pneumococcal disease as well as HPV-associated diseases.

References

Douglas R . Pneumonia in Papua New Guinea, from the past to the future. P N G Med J. 2012; 53(3-4):99-105. View

Kreimer A, Sampson J, Porras C, Schiller J, Kemp T, Herrero R . Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. J Natl Cancer Inst. 2020; 112(10):1038-1046. PMC: 7566548. DOI: 10.1093/jnci/djaa011. View

Borrow R, Heath P, Siegrist C . Use of pneumococcal polysaccharide vaccine in children: what is the evidence?. Curr Opin Infect Dis. 2012; 25(3):292-303. DOI: 10.1097/QCO.0b013e3283531b0f. View

Toh Z, Kosasih J, Russell F, Garland S, Mulholland E, Licciardi P . Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus. Infect Drug Resist. 2019; 12:1951-1967. PMC: 6613616. DOI: 10.2147/IDR.S178381. View

Temple B, Trong Toan N, Thi Trang Dai V, Bright K, Licciardi P, Marimla R . Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial. Lancet Infect Dis. 2019; 19(5):497-509. PMC: 6484092. DOI: 10.1016/S1473-3099(18)30734-5. View

Vorsters A, Van Damme P, Bosch F . HPV vaccination: Are we overlooking additional opportunities to control HPV infection and transmission?. Int J Infect Dis. 2019; 88:110-112. DOI: 10.1016/j.ijid.2019.09.006. View

Pomat W, van den Biggelaar A, Phuanukoonnon S, Francis J, Jacoby P, Siba P . Safety and immunogenicity of neonatal pneumococcal conjugate vaccination in Papua New Guinean children: a randomised controlled trial. PLoS One. 2013; 8(2):e56698. PMC: 3579820. DOI: 10.1371/journal.pone.0056698. View

Temple B, Nation M, Thi Trang Dai V, Beissbarth J, Bright K, Dunne E . Effect of a 2+1 schedule of ten-valent versus 13-valent pneumococcal conjugate vaccine on pneumococcal carriage: Results from a randomised controlled trial in Vietnam. Vaccine. 2021; 39(16):2303-2310. PMC: 8052188. DOI: 10.1016/j.vaccine.2021.02.043. View

Licciardi P, Toh Z, Clutterbuck E, Balloch A, Marimla R, Tikkanen L . No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccine. J Allergy Clin Immunol. 2016; 137(6):1772-1779.e11. PMC: 4899320. DOI: 10.1016/j.jaci.2015.12.1303. View

10.

Soohoo M, Blas M, Byraiah G, Carcamo C, Brown B . Cervical HPV Infection in Female Sex Workers: A Global Perspective. Open AIDS J. 2014; 7:58-66. PMC: 3915319. DOI: 10.2174/1874613601307010058. View

11.

Machalek D, Poynten M, Jin F, Fairley C, Farnsworth A, Garland S . Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol. 2012; 13(5):487-500. DOI: 10.1016/S1470-2045(12)70080-3. View

12.

Tabrizi S, Brotherton J, Kaldor J, Skinner S, Cummins E, Liu B . Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis. 2012; 206(11):1645-51. DOI: 10.1093/infdis/jis590. View

13.

ODempsey T, McArdle T, Ceesay S, Banya W, Demba E, Secka O . Immunization with a pneumococcal capsular polysaccharide vaccine during pregnancy. Vaccine. 1996; 14(10):963-70. DOI: 10.1016/0264-410x(96)00009-6. View

14.

Patel C, Brotherton J, Pillsbury A, Jayasinghe S, Donovan B, Macartney K . The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?. Euro Surveill. 2018; 23(41). PMC: 6194907. DOI: 10.2807/1560-7917.ES.2018.23.41.1700737. View

15.

Dehlendorff C, Baandrup L, Kjaer S . Real-World Effectiveness of Human Papillomavirus Vaccination Against Vulvovaginal High-Grade Precancerous Lesions and Cancers. J Natl Cancer Inst. 2020; 113(7):869-874. PMC: 8246827. DOI: 10.1093/jnci/djaa209. View

16.

Leach A, Mulholland E, Santosham M, Torzillo P, Brown N, McIntyre P . Pneumococcal conjugate vaccines PREVenar13 and SynflorIX in sequence or alone in high-risk Indigenous infants (PREV-IX_COMBO): protocol of a randomised controlled trial. BMJ Open. 2015; 5(1):e007247. PMC: 4298104. DOI: 10.1136/bmjopen-2014-007247. View

17.

Zhou J, Sun X, Stenzel D, Frazer I . Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 1991; 185(1):251-7. DOI: 10.1016/0042-6822(91)90772-4. View

18.

Binks M, Moberley S, Balloch A, Leach A, Nelson S, Hare K . PneuMum: Impact from a randomised controlled trial of maternal 23-valent pneumococcal polysaccharide vaccination on middle ear disease amongst Indigenous infants, Northern Territory, Australia. Vaccine. 2015; 33(48):6579-87. DOI: 10.1016/j.vaccine.2015.10.101. View

19.

Brotherton J, Budd A, Rompotis C, Bartlett N, Malloy M, Andersen R . Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis. Papillomavirus Res. 2019; 8:100177. PMC: 6658930. DOI: 10.1016/j.pvr.2019.100177. View

20.

Osborne S, Tabrizi S, Brotherton J, Cornall A, Wark J, Wrede C . Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program. Vaccine. 2014; 33(1):201-8. DOI: 10.1016/j.vaccine.2014.10.045. View